QU

QuantaMatrix Incorporated

IVD specialist in rapid antimicrobial susceptibility testing for critical infections like sepsis.

317690 | KO

Overview

Corporate Details

ISIN(s):
KR7317690006
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 131 B동 16층(가산동, 비와이씨하이시티), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

QuantaMatrix Inc. is an in-vitro diagnostics (IVD) company specializing in innovative solutions for clinical microbiology. The company develops and manufactures medical devices that utilize proprietary technologies, including time-lapse microscopic imaging and microfluidics, to accelerate pathogen identification and antimicrobial susceptibility testing (AST). Its primary focus is on critical infections such as sepsis, with its dRAST™ (direct Rapid Antimicrobial Susceptibility Test) system designed to provide results significantly faster than conventional methods. By enabling quicker and more accurate diagnoses, QuantaMatrix aims to improve patient outcomes, facilitate timely antibiotic treatment, and help combat antimicrobial resistance. The company's platforms also serve molecular and immunoassay applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 881.8 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 5.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 80.3 KB
2025-07-17 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-07-15 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]수시공시의무관련사항(공정공시) (유상증자 계획)
Korean 11.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 960.9 KB
2025-03-28 00:00
AGM Information
정기주주총회결과
Korean 24.1 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 167.0 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-12 00:00
Legal Proceedings Report
파생상품거래손실발생
Korean 6.8 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.9 KB

Automate Your Workflow. Get a real-time feed of all QuantaMatrix Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for QuantaMatrix Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for QuantaMatrix Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea
234080
JW PHARMACEUTICAL Logo
South Korea
001060
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.